viernes, 19 de noviembre de 2010

PARP inhibitor MK4827 shows antitumor activity in first trial in humans

A new drug that targets proteins responsible for helping cancer cells to repair damage to their DNA has shown promising anti-tumour activity in its first trial in humans.

Some patients with a range of solid tumours, many of whom had been treated unsuccessfully for their cancer with other therapies, have seen their tumours shrink or stabilise for periods of between 46 days to more than a year. The research will be presented at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Berlin today .